Biohit OyjLTS:0DRP +0.20%78 Interest Coverage is 18.00 as of Dec. 2025, which is 75% below its 10-year median of 71.29. GuruFocus rates LTS:0DRP with a GF Score™ of 78/100 and a GF Value™ of €2.76 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Biohit Oyj ranks worse than 51.18% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Biohit Oyj's
Operating Income
for the
six
months ended in Dec. 2025 was €1.80 Mil. Biohit Oyj's Interest Expense for the
six
months ended in Dec. 2025 was €-0.10 Mil.
Biohit Oyj's interest coverage for the quarter that ended in Dec. 2025 was 18.00.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Biohit Oyj's Interest Coverage or its related term are showing as below:
LTS:0DRP'
s Interest Coverage Range Over the Past 10 Years
Min: 3.91 Med: 71.29 Max: No Debt
Current: 15
LTS:0DRP's Interest Coverage is ranked worse than 51.18% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 15.72
vs LTS:0DRP: 15.00
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Biohit Oyj Interest Coverage Related Terms
Biohit Oyj Interest Coverage Historical Data
* Premium members only.
The historical data trend for Biohit Oyj's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
LTS:0DRP vs ABT, SYK, MDT: Interest Coverage Comparison
For the Medical Devices subindustry, Biohit Oyj's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biohit Oyj Interest Coverage vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biohit Oyj's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Biohit Oyj's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biohit Oyj (LTS:0DRP) has a Interest Coverage of 18.00 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Biohit Oyj and its competitors. This is 75% below median its historical median of 71.29. Over the past decade, Biohit Oyj's Interest Coverage has ranged from 3.91 to 10,000.00. According to the industry distribution chart, Biohit Oyj ranks #239 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 51.2%.
Is Biohit Oyj's Interest Coverage too high?
Biohit Oyj's current Interest Coverage of 18.00 is 75% below median its 10-year median of 71.29. Over the past 10 years, this metric has ranged from a low of 3.91 to a high of 10,000.00. The Medical Devices & Instruments industry median Interest Coverage is 15.72. Biohit Oyj's value of 18.00 is 14.5% above this industry median. Based on the distribution chart, Biohit Oyj ranks #239 out of 467 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Biohit Oyj has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's Interest Coverage compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Biohit Oyj ranks #239 out of 467 companies for Interest Coverage. This places Biohit Oyj in the lower half of its industry. The industry median Interest Coverage is 15.72. Biohit Oyj's value of 18.00 is 14.5% above this benchmark. Historically, Biohit Oyj's own Interest Coverage has ranged from 3.91 to 10,000.00 over the past decade. While the company's 10-year median is 71.29 vs. the industry median of 15.72, Biohit Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Devices & Instruments company?
The median Interest Coverage among Medical Devices & Instruments companies is 15.72, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biohit Oyj's current Interest Coverage of 18.00 is 14.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Biohit Oyj and its competitors. For the Medical Devices & Instruments industry, the median Interest Coverage is 15.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biohit Oyj's current Interest Coverage is 18.00, which is 75% below median its own 10-year median of 71.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.76, compared to a current price of €2.47 — trading 10.5% below its estimated fair value. The current Interest Coverage is 18.00, which is 75% below median its 10-year median of 71.29 and 14.5% above the Medical Devices & Instruments industry median of 15.72. Biohit Oyj's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current Interest Coverage is 18.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?
Based on GuruFocus' analysis, Biohit Oyj stock appears to be undervalued.
The current stock price of €2.47 is trading 10.5% below its estimated GF Value™ of €2.76.
GuruFocus considers Biohit Oyj to be Modestly Undervalued.
Key valuation signals for LTS:0DRP:
Interest Coverage: 18.00 (75% below median its 10-year median of 71.29)
GF Value™: €2.76 vs. price of €2.47 (10.5% below fair value)
Industry Position: 14.5% above the Medical Devices & Instruments median (#239 of 467)
No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
78GF Score
Get the complete analysis for LTS:0DRP
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRP has been successfully added to your 
